1. Home
  2. NEO vs NVCR Comparison

NEO vs NVCR Comparison

Compare NEO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$8.40

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$17.52

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEO
NVCR
Founded
2001
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Precision Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
NEO
NVCR
Price
$8.40
$17.52
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
$13.38
$28.08
AVG Volume (30 Days)
2.1M
1.7M
Earning Date
04-28-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
N/A
$655,353,000.00
Revenue This Year
$10.63
$7.72
Revenue Next Year
$9.73
$6.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.28
52 Week Low
$4.72
$9.82
52 Week High
$13.74
$20.05

Technical Indicators

Market Signals
Indicator
NEO
NVCR
Relative Strength Index (RSI) 46.83 66.39
Support Level $7.50 $12.66
Resistance Level $8.84 $18.92
Average True Range (ATR) 0.55 1.04
MACD -0.07 0.13
Stochastic Oscillator 10.44 80.98

Price Performance

Historical Comparison
NEO
NVCR

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: